TherapeuticsMD Files Q3 2024 10-Q
Ticker: TXMD · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 25743
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceutical
TL;DR
TXMD filed its Q3 10-Q. All systems go.
AI Summary
TherapeuticsMD, Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as AMHN, Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 951 Yamato Road, Suite 220, Boca Raton, FL 33431.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for TherapeuticsMD, Inc. for the third quarter of 2024.
Risk Assessment
Risk Level: low — This filing is a standard quarterly report and does not contain immediate, high-impact news.
Key Players & Entities
- TherapeuticsMD, Inc. (company) — Registrant
- AMHN, Inc. (company) — Former company name
- 20240930 (date) — Quarterly period end date
- 001-00100 (other) — Commission File Number
- 951 YAMATO ROAD, SUITE 220 (address) — Business and Mail Address
- BOCA RATON (location) — City for Business and Mail Address
- FL (location) — State for Business and Mail Address
- 33431 (other) — ZIP code for Business and Mail Address
FAQ
What is the reporting period for this 10-Q filing?
The quarterly period ended September 30, 2024.
What is the Commission File Number for TherapeuticsMD, Inc.?
The Commission File Number is 001-00100.
In which state is TherapeuticsMD, Inc. incorporated?
TherapeuticsMD, Inc. is incorporated in Nevada.
What is the primary business address of TherapeuticsMD, Inc.?
The business address is 951 Yamato Road, Suite 220, Boca Raton, FL 33431.
What was a former name of TherapeuticsMD, Inc.?
A former name of TherapeuticsMD, Inc. was AMHN, Inc.
Filing Stats: 4,581 words · 18 min read · ~15 pages · Grade level 14.8 · Accepted 2024-11-12 16:16:35
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share TXMD The Nasdaq Stock Market
Filing Documents
- ea0218728-10q_therapeutics.htm (10-Q) — 544KB
- ea021872801ex31-1_therap.htm (EX-31.1) — 9KB
- ea021872801ex31-2_therap.htm (EX-31.2) — 9KB
- ea021872801ex32-1_therap.htm (EX-32.1) — 4KB
- ea021872801ex32-2_therap.htm (EX-32.2) — 4KB
- 0001213900-24-096811.txt ( ) — 4191KB
- txmd-20240930.xsd (EX-101.SCH) — 46KB
- txmd-20240930_cal.xml (EX-101.CAL) — 37KB
- txmd-20240930_def.xml (EX-101.DEF) — 207KB
- txmd-20240930_lab.xml (EX-101.LAB) — 392KB
- txmd-20240930_pre.xml (EX-101.PRE) — 221KB
- ea0218728-10q_therapeutics_htm.xml (XML) — 429KB
- Financial Information
Part I - Financial Information Item 1.
Financial statements (unaudited)
Financial statements (unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.
Management's discussion and analysis of financial condition and results of operations
Management's discussion and analysis of financial condition and results of operations 17 Item 3.
Quantitative and qualitative disclosures about market risk
Quantitative and qualitative disclosures about market risk 27 Item 4.
Controls and procedures
Controls and procedures 27
- Other Information
Part II - Other Information Item 1.
Legal proceedings
Legal proceedings 28 Item 1A.
Risk factors
Risk factors 28 Item 2. Unregistered sales of equity securities and use of proceeds 28 Item 3. Defaults upon senior securities 28 Item 4. Mine safety disclosures 28 Item 5. Other information 28 Item 6. Exhibits 29
- Financial Information
Part I - Financial Information
Financial statements
Item 1. Financial statements TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except per share data) September 30, 2024 December 31, 2023 (Unaudited) Assets: Current assets: Cash and cash equivalents $ 5,047 $ 4,327 Royalty receivable, current portion 3,323 3,090 Prepaid and other current assets 3,784 4,035 Current assets of discontinued operations — 344 Total current assets 12,154 11,796 License rights and other intangible assets, net 4,428 6,098 Right of use assets 6,302 6,873 Royalty receivable, long term 16,610 18,484 Other non-current assets 58 58 Total assets $ 39,552 $ 43,309 Liabilities and stockholders' equity: Current liabilities: Accounts payable $ 234 $ 27 Accrued expenses and other current liabilities 2,818 3,133 Current liabilities of discontinued operations 2,924 3,694 Total current liabilities 5,976 6,854 Operating lease liabilities 5,777 6,532 Other non-current liabilities 705 636 Total liabilities 12,458 14,022 Commitments and contingencies (Note 6) Stockholders' equity: Common stock, par value $ 0.001 ; 32,000 shares authorized, 11,532 issued and outstanding as of September 30, 2024 and December 31, 2023 11 11 Additional paid-in capital 979,157 978,917 Accumulated deficit ( 952,074 ) ( 949,641 ) Total stockholders' equity 27,094 29,287 Total liabilities and stockholders' equity $ 39,552 $ 43,309 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 TherapeuticsMD, Inc. and Subsidiaries Condensed Consolidated Statements of Operations (Unaudited - in thousands, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue, net: License and service revenue $ 547 $ ( 53 ) $ 1,094 $ 800 Operating expenses: Selling, general and administrative 1,310 1,590 3,865 7,427 Imp